After hours: 4:11PM EDT
|Bid||46.56 x 800|
|Ask||47.49 x 3200|
|Day's Range||46.68 - 47.75|
|52 Week Range||35.10 - 48.11|
|Beta (3Y Monthly)||0.91|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
NEW YORK, March 05, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Hologic, Inc. (HOLX) announced today that it has received a CE mark in Europe for its Omni™ hysteroscope, an innovative three-in-one modular scope with advanced visualization capabilities designed for both diagnostic and therapeutic hysteroscopic procedures. Obstetricians and gynecologists (ObGyns) can use the new Omni hysteroscope in out- and in-patient settings. “Experts agree that direct visualization of the uterine cavity in women with abnormal uterine bleeding is the gold standard that allows ObGyns to accurately identify and collect quality samples and remove pathology – in a safer and more effective manner than blind biopsy and curettage,”1 said Edward Evantash, M.D., Medical Director and Vice President of Global Medical Affairs, Hologic.
Hologic, Inc. (HOLX) announced today that its Aptima® HIV-1 Quant Dx Assay has received two new CE marks in Europe – for early infant diagnosis (EID) and for testing dried blood spots (DBS). This means the assay can be used to qualitatively detect HIV-1 RNA as an aid in the diagnosis of HIV-1 infected infants under 18 months old, and to test an additional sample type (DBS) to monitor viral load and disease progression in HIV-1 infected individuals in European and African countries. It is the first and only dual-claim assay for both viral load and early infant diagnosis.
-- FDA clearance makes clinically validated assay available for sexually-transmitted infection listed as emerging threat by the CDC --
NEW YORK, Jan. 17, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Hologic, Inc. announced today that the Company plans to release its financial results for the first quarter of fiscal 2019 on Wednesday, January 30, 2019, after the market closes.
Hologic, Inc. (HOLX) announced today preliminary revenue results for its first fiscal quarter ended December 29, 2018. The Company expects to report total revenues of approximately $831 million, an increase of 5% compared to the prior year period, or 5.7% in constant currency.
Hologic, Inc. announced today that the Company will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, January 8, 2019 at 11:30 a.m.
Hologic, Inc.’s (Nasdaq: HOLX) Cynosure division announced today the North American launch of the FDA-cleared TempSure™ Surgical RF technology, a new offering of the TempSure™ radiofrequency (RF) platform that provides clinicians the ability to perform both surgical and non-surgical aesthetic procedures across a variety of specialties, on a single device. Cynosure also has returned TempSure™ Vitalia hand pieces and probes to the market and will continue to market its MonaLisa Touch® CO2 laser following the U.S. Food and Drug Administration (FDA) inquiry on products used in energy-based women’s health procedures.
Hologic, Inc. (HOLX) announced today that a Massachusetts Superior Court granted a preliminary injunction in lawsuits against Chinese X-ray equipment provider Direct Digital Imaging Technology (Beijing), Inc. (DDIT) and a former Hologic employee, Lawrence Ibbetson, for alleged misappropriation of trade secrets. Hologic alleges that DDIT and Ibbetson misappropriated trade secrets for selenium coating technology used in the detectors within Hologic's Selenia® Dimensions® and 3Dimensions™ mammography systems.
NEW YORK, Dec. 12, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Flexible, modular design with powerful visualization gives doctors a single device with three sheath options to both diagnose and treat patients
Hologic, Inc. (HOLX) will showcase its expanding suite of breast and skeletal health products, including screening, interventional, ultrasound and surgical solutions, in Booth #2511 at the 104th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) at McCormick Place in Chicago from Nov. 25 to 29. The pioneer behind the Genius™ 3D Mammography™ exam, Hologic has expanded significantly in recent years to offer innovations across the entire clinical continuum of breast health. In addition, two recent acquisitions of Faxitron® Bioptics, a leader in digital specimen radiography, and Focal Therapeutics, manufacturer of the BioZorb® marker, have enabled Hologic to play a larger role in breast conserving surgery and strengthened its offerings to radiologists, pathologists and breast surgeons.
Hologic, Inc. (HOLX) announced today that Ludwig N. Hantson has been elected to the Company’s Board of Directors, effective immediately. Dr. Hantson, who has more than 30 years of experience in the life sciences industry, is the Chief Executive Officer of Alexion Pharmaceuticals, Inc., a publicly-traded global biopharmaceutical company. Before joining Alexion, Dr. Hantson was President and Chief Executive Officer of Baxalta Incorporated.
Hologic, Inc. announced today that the Company will present at the 30th Annual Piper Jaffray Healthcare Conference in New York, NY on Wednesday, November 28 at 8 a.m.
NEW YORK, Nov. 09, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Hologic, Inc. announced today that the Company will present at the Stifel 2018 Healthcare Conference in New York, NY on Tuesday, November 13 at 8 a.m. Eastern Time.
Hologic, Inc. announced today that the Company plans to release its financial results for the fourth quarter of fiscal 2018 on Wednesday, November 7, 2018, after the market closes.
Survey commissioned by Company behind the Genius™ 3D Mammography™ exam sheds light on need for education during Breast Cancer Awareness Month MARLBOROUGH, Mass. , Oct. 1, 2018 /PRNewswire/ -- WHO: ...
Hologic, Inc. (HOLX) announced today that Nancy G. Brinker, global cancer advocate, Hologic consultant and founder of Susan G. Komen, and Krystal Barter, author and founder of Australian nonprofit Pink Hope, will join Steve MacMillan, the Company’s Chairman, President and Chief Executive Officer, and selected employees to ring the Nasdaq Opening Bell for the 13th consecutive year on October 1 to mark the start of Breast Cancer Awareness Month. In addition to appearing at the Nasdaq MarketSite, Hologic will recognize Breast Cancer Awareness Month by announcing the results from their recent survey, conducted online by The Harris Poll among over 1,000 U.S. women, designed to highlight the need for education about breast density and the effect it has on breast cancer screening and cancer detection.
Hologic, Inc. (HOLX), a global leader in women’s health, announced today that it has signed a definitive agreement to acquire Focal Therapeutics, a privately-held company, for $125 million in cash. In conjunction with Hologic’s recent acquisition of Faxitron Bioptics, Focal strengthens the Company’s position in the rapidly growing market for breast conserving surgery. The transaction adds Focal’s innovative BioZorb marker to the Company’s Breast Health product portfolio.